Baseline differences between patients with and without evidence of cardiac involvement in the derivation cohort
| . | Absence of cardiac involvement (n = 133) . | Presence of cardiac involvement (n = 116) . | P . | ||
|---|---|---|---|---|---|
| Number (%) . | Median (25%-75%) . | Number (%) . | Median (25%-75%) . | ||
| General characteristics | |||||
| Male sex | 68 (51) | 68 (59) | .2 | ||
| Age | 65 (59-71) | 65 (60-70) | .051 | ||
| BMI, kg/m2 | 28.0 (22.3.6-32.6) | 26.3 (23.5-29.8) | .03 | ||
| Amyloidosis involvement | |||||
| Chain type, κ/λ* | 44/88 | 15/101 | <.001 | ||
| Peripheral nervous system involvement | 8 (6) | 15 (13) | .048 | ||
| Autonomic nervous system involvement | 11 (8) | 26 (22) | .001 | ||
| Kidney involvement | 86 (64) | 74 (63) | .9 | ||
| Medical history | |||||
| Atrial fibrillation | 15 (11) | 21 (18) | .1 | ||
| Hypertension | 73 (54) | 38 (32) | <.001 | ||
| Diabetes | 12 (9) | 12 (10) | .7 | ||
| Coronary artery disease | 10 (9) | 16 (14) | .1 | ||
| Stroke | 2 (2) | 8 (7) | .03 | ||
| Functional status | |||||
| NYHA class | <.001 | ||||
| I | 111 (83) | 53 (46) | |||
| II | 18 (14) | 43 (37) | |||
| III | 4 (3) | 20 (17) | |||
| Laboratory studies | |||||
| FLC-diff | 13.4 (5.1-34.9) | 28.4 (6.3-93.8) | .008 | ||
| BNP, pg/mL | 54 (26-103) | 181 (94-529) | <.001 | ||
| NT-proBNP, pg/mL | 181 (74-604) | 1313 (451-4193) | <.001 | ||
| Troponin I, ng/mL | 0.006 (0.006-0.015) | 0.041 (0.012-0.116) | <.001 | ||
| eGFR, mL/min/1.73 m2 | 69 (37-86) | 60 (38-81) | .3 | ||
| Transthoracic echocardiography | |||||
| IVSd, mm | 9 (8-10) | 12 (11-14) | <.001 | ||
| Ejection fraction, % | 65 (60-69) | 60 (50-65) | .003 | ||
| . | Absence of cardiac involvement (n = 133) . | Presence of cardiac involvement (n = 116) . | P . | ||
|---|---|---|---|---|---|
| Number (%) . | Median (25%-75%) . | Number (%) . | Median (25%-75%) . | ||
| General characteristics | |||||
| Male sex | 68 (51) | 68 (59) | .2 | ||
| Age | 65 (59-71) | 65 (60-70) | .051 | ||
| BMI, kg/m2 | 28.0 (22.3.6-32.6) | 26.3 (23.5-29.8) | .03 | ||
| Amyloidosis involvement | |||||
| Chain type, κ/λ* | 44/88 | 15/101 | <.001 | ||
| Peripheral nervous system involvement | 8 (6) | 15 (13) | .048 | ||
| Autonomic nervous system involvement | 11 (8) | 26 (22) | .001 | ||
| Kidney involvement | 86 (64) | 74 (63) | .9 | ||
| Medical history | |||||
| Atrial fibrillation | 15 (11) | 21 (18) | .1 | ||
| Hypertension | 73 (54) | 38 (32) | <.001 | ||
| Diabetes | 12 (9) | 12 (10) | .7 | ||
| Coronary artery disease | 10 (9) | 16 (14) | .1 | ||
| Stroke | 2 (2) | 8 (7) | .03 | ||
| Functional status | |||||
| NYHA class | <.001 | ||||
| I | 111 (83) | 53 (46) | |||
| II | 18 (14) | 43 (37) | |||
| III | 4 (3) | 20 (17) | |||
| Laboratory studies | |||||
| FLC-diff | 13.4 (5.1-34.9) | 28.4 (6.3-93.8) | .008 | ||
| BNP, pg/mL | 54 (26-103) | 181 (94-529) | <.001 | ||
| NT-proBNP, pg/mL | 181 (74-604) | 1313 (451-4193) | <.001 | ||
| Troponin I, ng/mL | 0.006 (0.006-0.015) | 0.041 (0.012-0.116) | <.001 | ||
| eGFR, mL/min/1.73 m2 | 69 (37-86) | 60 (38-81) | .3 | ||
| Transthoracic echocardiography | |||||
| IVSd, mm | 9 (8-10) | 12 (11-14) | <.001 | ||
| Ejection fraction, % | 65 (60-69) | 60 (50-65) | .003 | ||
One patient did not have light chain typing performed.